Kala Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to create a corticosteroid designed for ocular applications, resulting in two product candidates in Phase 3 clinical development, KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005461/en/
Source:
Investors and Media:
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
cduong@macbiocom.com